Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):745-58. doi: 10.1517/17425255.2012.686603. Epub 2012 May 16. Review.

PMID:
22587686
[PubMed - indexed for MEDLINE]
2.

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS.

Vasc Health Risk Manag. 2013;9:273-82. doi: 10.2147/VHRM.S44330. Epub 2013 May 29. Review.

PMID:
23761972
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Scheen AJ.

Clin Pharmacokinet. 2010 Sep;49(9):573-88. doi: 10.2165/11532980-000000000-00000. Review.

PMID:
20690781
[PubMed - indexed for MEDLINE]
4.

Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.

Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA.

Eur J Clin Pharmacol. 2013 Jul;69(7):1401-9. doi: 10.1007/s00228-013-1475-y. Epub 2013 Feb 14.

PMID:
23407853
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study.

Kandhwal K, Dey S, Nazarudheen S, Arora R, Reyar S, Thudi NR, Monif T, Singh MK, Rao S.

Clin Drug Investig. 2011 Dec 1;31(12):853-63. doi: 10.2165/11592920-000000000-00000.

PMID:
21919543
[PubMed - indexed for MEDLINE]
6.

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.

J Am Heart Assoc. 2013 Jan 28;2(1):e003277. doi: 10.1161/JAHA.112.003277.

PMID:
23525426
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1265-76. doi: 10.1517/17425255.2010.513699. Review.

PMID:
20707611
[PubMed - indexed for MEDLINE]
8.

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Q, Matthews CZ, Wagner JA, Gottesdiener KM.

Clin Drug Investig. 2010;30(12):855-66. doi: 10.2165/11538410-000000000-00000.

PMID:
20923244
[PubMed - indexed for MEDLINE]
9.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

Scheen AJ.

Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. Review.

PMID:
20590741
[PubMed - indexed for MEDLINE]
11.

Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction.

Bhome R, Penn H.

Diabet Med. 2012 May;29(5):693-4. doi: 10.1111/j.1464-5491.2011.03502.x. No abstract available.

PMID:
22023482
[PubMed - indexed for MEDLINE]
12.

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E.

Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14.

PMID:
23439744
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

Bailey CJ, Green BD, Flatt PR.

Expert Opin Investig Drugs. 2010 Aug;19(8):1017-25. doi: 10.1517/13543784.2010.505235. Review.

PMID:
20629618
[PubMed - indexed for MEDLINE]
14.

The effects of simvastatin on the pharmacokinectics of sitagliptin.

Cerra M, Luo WL, Li SX, Matthews C, O'Neill EA, Wagner JA, Stoch SA, Anderson MS.

J Popul Ther Clin Pharmacol. 2012;19(3):e356-60. Epub 2012 Oct 11.

PMID:
23077137
[PubMed - indexed for MEDLINE]
Free Article
15.

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

Chwieduk CM.

Drugs. 2011 Feb 12;71(3):349-61. doi: 10.2165/11206060-000000000-00000. Review.

PMID:
21319871
[PubMed - indexed for MEDLINE]
16.

New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

Green J, Feinglos M.

Vasc Health Risk Manag. 2008;4(4):743-51. Review.

PMID:
19065992
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.

Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H; Japanese Elderly Diabetes Intervention Trial Research Group.

Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:88-102. doi: 10.1111/j.1447-0594.2011.00816.x.

PMID:
22435944
[PubMed - indexed for MEDLINE]
18.

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.

McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P; IN-PRACTICE study.

Int J Clin Pract. 2010 Jul;64(8):1052-61. doi: 10.1111/j.1742-1241.2010.02429.x. Epub 2010 May 12.

PMID:
20487050
[PubMed - indexed for MEDLINE]
19.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

PMID:
23748503
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk